You must have the latest - Flash plugin - to view this slideshow. 63-year history of research and clinical excellence

FDA approves first targeted drug for advanced stomach cancer

April 21, 2014

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration (FDA) approved a targeted drug for advanced stomach cancer.

employee receiving a flu shot 

Dana-Farber achieves 100 percent compliance for flu vaccinations

Last fall, Dana-Farber was lauded by the Boston Globe for having the highest vaccination rate in 2013 among Massachusetts hospitals, with 99 percent of staff receiving a flu vaccine. For the 2013-14 flu season, Dana-Farber did even better — achieving 100 percent compliance for flu vaccinations. "I am very proud of our employees for continuing to embrace our efforts to bring the Institute's flu policy in line with our other safety measures for averting the spread of preventable infection," says Dana-Farber President and CEO Edward J. Benz Jr., MD. "Universal compliance should be every hospital's goal, and I am happy once again with our leadership in this area."

Dana-Farber researchers uncover link between Down syndrome and leukemia
April 20, 2014

A team of researchers led by Dana-Farber Cancer Institute investigators has uncovered a connection between people with Down syndrome and having a heightened risk of developing acute lymphoblastic leukemia (ALL) during childhood.

Scientists find potential drug targets in deadly pediatric brain tumors
April 06, 2014

Researchers studying a rare, always fatal brain tumor in children have found several molecular alterations that drive the cancer, according to a new study from scientists at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and McGill University. The findings, published in Nature Genetics, identify potential new targets for drug treatments.

Study identifies lung cancer patients likely to benefit from potential immune system-based therapy
April 06, 2014

Investigators at Dana-Farber led by Leena Gandhi, MD, PhD, report a promising way of predicting which patients with non-small cell lung cancer (NSCLC) are most likely to benefit from a drug that frees up an immune system attack on tumor cells.

Lilly’s Gastric Cancer Drug Wins Sales Clearance From U.S. FDA (Bloomberg News)

April 22, 2014

Dr. Charles Fuchs led a study of ramucirumab, the first targeted drug for advanced stomach cancer to secure FDA approval.

Elizabeth Warren Calls for More Federal Research Money (BU Today)
April 16, 2014

At a meeting with Senator Elizabeth Warren, Dr. Barrett Rollins warned that young researchers were abandoning the field or taking jobs in more research-generous countries.

Immunotherapy Passes Early Tests in NSCLC (MedPage Today)
April 10, 2014

Dr. Leena Gandhi reported at the AACR meeting on a study showing a cancer immunotherapy that passed a key test in patients with lung cancer.

Breast Cancer Drug Results As Impressive As I've Ever Seen Researcher Says (NY Times)
April 06, 2014

Dr. Judy Garber and Dr. Eric Winer commented on an experimental medicine that has slowed the pace of advanced breast cancer, doubling the amount of time that patients could live without their tumors advancing.

Cancer between the Lines Video Project for Young Adults

April 28, 2014

1:00 PM - 5:00 PM

Dana Building, Lower Level


Young adults coping with cancer can face a variety of challenges, including communicating with their caregivers. The Young Adults Program at Dana-Farber invites young adult patients to share the aspects of human connection that play a role in the experience of cancer. "Cancer between the Lines" will provide a platform to recognize, honor, and share the unique narratives of young adult patients and their caregivers at Dana-Farber. Patients and their primary or medical caregivers can participate in recorded conversations. For more information or to reserve a spot, call 617-632-6819 or email



Dana-Farber's Mammography Van(27)

April 23, 2014

9:00 AM - 10:00 AM

Joseph Smith Community Health Center - Waltham

Our experts offer mammograms to women 40 years of age and older. For more information or to make an appointment, call Dana-Farber's Mammography Van office during regular business hours 9:00 a.m. – 5:30 p.m. at 617-632-1974 or e-mail


Port in the Storm: How to Make a Medical Decision and Live to Tell About It by Cole A. Giller, MD, PhD, a book discussion

April 23, 2014

11:00 AM - 12:00 PM

Blum Resource Center, Yawkey Center, Floor 1

Interpreting data, weighing trade-offs, clarifying your beliefs and values are all factors that come into play when we make choices about our health. A discussion of these and other factors that go into decision-making are discussed in this book. Free copies of this book are available for pre-registered participants while supplies last. Pick up your copy at the Blum Resource Center. Participants are welcome to attend whether or not they’ve read the book. 

To register or for more information, contact Sarah Singer @ 617-632-3751 or 



Neuroedocrine and Carcinoid Seminar Support Group Series

April 23, 2014

12:00 PM - 2:00 PM

Smith Building 330

A series devoted to patients and families affected by neuroendocrine and carcinoid tumors. Patients are caregivers and invited for the first hour. Separate patient and caregiver discussion groups follow during the second hour.

Jane Bausch, LICSW and Susan Englander, LISCW 

Seminar 12:00 PM - 1:00PM

Seperate patient and caregivers 1:00 PM - 2:00 PM

Please call 617-632-3309 to register


  • Patient referral information, clinical resources and more.

  • Make an Appointment

    For adults:

    For children:

    Or complete the online form.

  • Clinical Trials

    Search current cancer clinical trials at Dana-Farber.

  • How to Help

    Yawkey Center for Cancer Care entrance 

    There are many ways to support Dana-Farber and the Jimmy Fund.

    give now button
  • Dana-Farber Blog

    Insight Blog screenshot 

    Insight features the latest in cancer care and research news from Dana-Farber.
    Read the blog

  • Dana-Farber eNewsletter

    Dana-Farber Spotlight 

    Stay current on the latest news by signing up for Spotlight, our email newsletter.
    View current issue
    Subscribe now